comparemela.com

Latest Breaking News On - Aurigene discovery technologies - Page 6 : comparemela.com

Olema Oncology, Aurigene collaborate to discover, develop novel cancer therapies

Olema will make an upfront licensing payment of $8 million for rights to a pre-existing Aurigene programme

Latest News | Dr Reddy s Arm Inks Pact with US-based Olema Pharmaceuticals

Get latest articles and stories on Latest News at LatestLY. Dr Reddy s Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of an undisclosed oncology target. Latest News | Dr Reddy s Arm Inks Pact with US-based Olema Pharmaceuticals.

Comparing Adagio Therapeutics (NASDAQ:ADGI) and Curis (NASDAQ:CRIS)

Adagio Therapeutics (NASDAQ:ADGI – Get Rating) and Curis (NASDAQ:CRIS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Institutional & Insider Ownership 88.7% of Adagio Therapeutics shares are […]

Head to Head Survey: Exelixis (NASDAQ:EXEL) & Qiagen (NYSE:QGEN)

Exelixis (NASDAQ:EXEL – Get Rating) and Qiagen (NYSE:QGEN – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Valuation & Earnings This table compares Exelixis and Qiagen’s top-line revenue, earnings […]

First Indian woman to climb five 8000+ peaks, Priyanka Mohite wants to go on and on

First Indian woman to climb five 8000+ peaks, Priyanka Mohite wants to go on and on
daijiworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from daijiworld.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.